Try our Advanced Search for more refined results
Life Sciences - March, 2019
330 articles
- Impax Payment Was Meant To Dodge Competition, FTC Says
- J&J's 3-Deal Day Signals A Shift In Legal War Over Talc
- Monsanto's Split-Trial Gamble Backfired With $80M Verdict
- 7 Firms To Steer 4 IPOs Led By PE-Backed Trading Platform
- Mylan Gets Some Parts Of Investors' EpiPen Suit Trimmed
- Legal Bruises Add Up For Trump's Health Policy Vision
- Valeant Wants Ex-NJ AG Knocked Off Stock-Drop Suit
- Del. Jury Clears Teva In $41M Orexo Drug Patent Suit
- Pelvic Mesh MDL Fee Committee Accused Of Self-Dealing
- DOJ Seeks Toss Of Whistleblower's Gilead FCA Case
- Medtox Class Gets Initial OK Of $1.6M Deal In TCPA Suit
- Deal Could End Investor Suit Over Alleged $47M Withdrawal
- Court Ruling Won't Stop PTAB's Review Of Vimovo Patent
- $448M Win In AbbVie Case Not Enough, FTC Tells 3rd Circ.
- 8 Insys Docs Tallied $28M In Medicare Costs, Jury Hears
- CFIUS 2.0 Roundup: The Pilot Program, The Shoulder Shrug
- Alkermes Beats Investor Suit Over Opioid Addiction Treatment
- WilmerHale Hires Back Former SEC Commish From Mylan
- Feds Slam Pharma Execs' Bid To Void Kickback Convictions
- Fresenius To Pay $231M To Resolve Foreign Bribery Charges
- Medtronic Wants Full Fed. Circ. To Undo $24M Spine IP Loss
- 3rd Roundup Trial Begins Day After $80M Monsanto Loss
- Pharma Cos. Owe $30M For Acquired Drug's Gains, Suit Says
- 3 Fights The Fed. Circ. Picked With The PTAB In 2018
- Fed. Circ. Revives Opana Patent Axed As Natural Law
- Biotech Exec Gets 2 Years For Embezzlement
- FDA Needs New Opioid Standards, Gottlieb Tells Senators
- J&J Can't Get Pa. Mesh Mistrial Over Expert's Heart Attack
- No Nucynta Generics Until 2025, Fed. Circ. Affirms
- 2 Firms Lead Precision BioSciences' $126M IPO
- Murky Akrimax Fraud Case Gets Some Clarity At Chancery
- Sacklers Illegally Siphoned Opioid Profits, NY's AG Says
- Brexit Risk-Disclosure Considerations For US Reporting Cos.
- There's More To Cosmetics Regulation Than Meets The Eye
- Stryker To Bring On Johnson & Johnson Exec For CLO Spot
- Expectations For Glyphosate Litigation After Monsanto Verdict
- J&J Settles 2 Asbestos-In-Talc Cases Mid-Trial
- Lawmakers Aim To Abandon Courts' Forbidden Patent Types
- 'Groundbreaking' AbbVie Suits Test Bold Anti-Generic Tactics
- 5th Circ. Won't Make Becton Pay Out Profits Over False Ads
- Real Estate Rumors: Baywood Hotels, Calmwater, Fluidigm
- Fed. Circ. Judges You Wanted On Your PTAB Appeal In 2018
- Kimberly-Clark Beats Whistleblower Suit Over Medical Gowns
- Monsanto Hit With $80M Verdict In First Fed. Roundup Trial
- Insys Exec Flung Phone Off Mountain To Hide Info, Jury Hears
- 'This Emperor Clearly Has No Clothes': 2018 In Patent Dissent
- J&J Wins Another Asbestos-In-Talc Trial In NJ
- Cooley, Linklaters Steer Biopharma Genfit's $135M Debut
- Clinic's Parent Co. Can't Arbitrate Destroyed Embryo Claims
- Novartis Whistleblower Keeps $1.5M Award, Still Faces Probe
- Allergan Gets Shire's Dry-Eye Drug Antitrust Suit Dropped
- Cephalon, Mylan, Ranbaxy Ink Combined $65.8M Provigil Deal
- AbbVie Wants Suit Alleging Kickbacks, Buyback Scheme Axed
- FTC Extends Scrutiny Of Bristol-Myers' $74B Celgene Buy
- Drug Store Not Liable In Side Effect Suit: Ill. Appeals Court
- J&J Tells Jury Greedy Lawyers Driving Asbestos-In-Talc Fight
- Chancery OKs New Stay For 'Dark' Insys Derivative Claims
- 'Send Monsanto A Message,' Jury Told At Roundup Trial's End
- The Federal Circuit In 2018: A By-The-Numbers Snapshot
- Express Scripts Owes $14M In Tax, Wash. Appeals Court Says
- 3M Settles Dentists' Defective Crown Suit For $32.5M
- Is Purdue's $270M Deal Beginning Of End For Opioid Cases?
- PTAB Upholds Skin Cancer Detection Patent
- Chancery Says It Won't Keep Takeda's Foreign Patent Fight
- Ex-Insys Rep Recounts Ties, Some Physical, To Founder
- These Firms Crushed It At The Federal Circuit In 2018
- Walgreens, Kroger Cut From J&J's Remicade Antitrust Fight
- Urine Big Trouble: Willfulness, Misconduct Spark $3M IP Loss
- 2nd Circ. Refuses To Revive Complaints In Eliquis MDL
- Purdue To Pay $270M To End Oklahoma AG's Opioid Suit
- And Now A Word From The Panel: An MDL Denial
- 'Imperfect' Treatment Result Not J&J Mesh's Fault, Jury Told
- Setting The Record Straight On Women In Court Reporting
- Natera Infringing Transplant Testing Patents, Stanford Says
- J&J And Plaintiff Ask 'What Is Asbestos?' As Talc Trial Opens
- Tufts Hires Ex-US Atty To Review Purdue, Sackler Influence
- Myriad Genetics Ditches Medicare Overbilling Stock-Drop Suit
- Atty Privilege Forces Uneasy Judge To Limit 2 Insys Witnesses
- Cancer Researcher Says Center Must Pay Up For Treatments
- Faulty Mesh Worsened Woman's Incontinence, Pa. Jury Hears
- Analogic Beats DOL's Pay Discrimination Claims
- Ex-Monsanto CEO Defends Roundup, Concedes Study Limits
- Boston Scientific OK To Fire Worker After DUI, 3rd Circ. Says
- Hahn Loeser Forms Ill. Biometric Privacy Practice Group
- Philly Judge Won't Boot Colleague From J&J Mesh Dispute
- DePuy Alleges Rival Induced Workers To Break Contracts
- J&J Talc Source Lifts Del. Ch. 11 Stay For Past Owner
- $660M Biotech Co. Merger Offer Is Too Low, Investors Say
- Trading Platform, Med Device Biz Prime IPOs Totaling $757M
- Ex-Aveo CFO Gets 2-Year Corporate Bar For Duping Investors
- Limiting Supreme Court's Size Is Not Enough
- Bayer, Janssen Pay $775M To End Xarelto Suits
- J&J Can't Avoid Vote On Shareholder Arbitration, Suit Says
- Monsanto Jury Hears Cancer Changed Couple's Lives
- Pharma Co. Reaches $3.6M Deal With Unsecured Creditors
- AVX Seeks Redo Of Greatbatch's $22M Pacemaker Patent Win
- Medtronic Warning Highlights Debate On FDA Cyber Policy
- Lamictal Antitrust Class Action Paused For Certification Fight
- Employers Can't Keep Arbitrations Secret, NLRB Judge Says
- Meet The Outspoken Judge Handling Epic Monsanto Case
- Lyft's $2B IPO Dominates Week That Could See 4 Deals Price
- Small Changes To Old Drugs Don't Extend Patents, ECJ Says
- MabVax Hits Ch. 11, Blaming Alleged $27M Pump-And-Dump
- Anixa Directors Say Option Price, Patent News Not Related
- Attys' Fees Trimmed To $1.3M In Vertex Junk Fax Settlement
- VC-Backed Turning Point Files $100M Cooley-Led IPO
- Vt. Can Move Ahead With Opioid Suit Against Purdue Pharma
- Swiss Firm Takes French Biotech Co. Private For €730.1M
- Omnicare's $20M Settlement With Investors Gets Initial OK
- 17 Alleged Misstatements Cut From Dr. Reddy's Investor Suit
- What To Know About New FDA Commissioner Sharpless
- Sens. Seek Answers About Doctor-Owned Medical Suppliers
- 1st Circ. Loss Dooms New Asacol Buyer Class, Allergan Says
- Rejected J&J Job Seeker Must Arbitrate Claim, 3rd Circ. Told
- Firms Contest Class Counsel Bid In Trevena Investor Suit
- Lenders Score Major High Court Victory In Foreclosure Case
- Trial Counsel's Role On A Mass Tort Virtual Law Team
- Law360's Life Sciences Editorial Advisory Board
- Tech Trends From SXSW Pose Unique Questions For Lawyers
- Health Care IP Key To Cutting Costs: FTC Member
- What's In A Judgeship? More Than Meets The Eye
- Swamped: How Magistrate Judges Salvaged Louisiana's Judicial Crisis
- Full Fed. Circ. Won't Review Stryker's $254M Damages Win
- Pointed Questions Suggest Longer FCA Time Limit Is Likely
- Teva's 'Strategic Decision' On FCA Testimony Gets Judge's Ire
- J&J Talc Supplier's Ex-Owners Ask For Ch. 11 Shield
- Monsanto Jury Told $63B Co. Should Pay Up Over Roundup
- Workers Can Sue Labs For Shoddy Drug Tests: SC Justices
- Dental Supply Co. Must Face Price-Fixing Suit, Investors Say
- Real Estate Rumors: Morgan Stanley, AEW, Stockbridge
- CMS Looks To End Pharma Co.'s Drug Classification Suit
- Insys Founder's Atty Seeks Mistrial Over Addiction Testimony
- Roche Accuses Health Co. Execs Of $87M Test Strip Fraud
- Testosterone Supplement Damaged Pa. Man's Liver, Suit Says
- Justices' Input Needed In ERISA Preemption Fight, Ark. Says
- In Bar Admissions Process, It's Candor Or Bust
- Off-Label Promotion Still A Litigation Risk For Pharma Cos.
- BakerHostetler DQ'd From Opioid MDL Bellwethers
- Allergan Urges Justices To Hear PTAB Tribal Immunity Suit
- J&J Talc Supplier Tort Claimants Fight Insurance Fund Bid
- 'In A Timely Manner': Three Decades Of Judgeship Bills
- From Showdowns To Hotlines, Frazzled Judges Get Creative
- Kaplan Fox Wins Lead In MiMedx 'Channel-Stuffing' Suit
- Abbott Must Face Analyst's Bias Claim, Illinois Panel Says
- Athenex Says FDA Wrongly Policing Practice Of Medicine
- Insys Opioid Prescriber Was Addicted Himself, Witness Says
- Asia, Huawei Dominating International Patents, WIPO Says
- Puma Biotech Owes $22M For Libel In Proxy Fight, Jury Says
- Justices Ponder FCA Ambiguities In Time Limit Case
- Monsanto's Roundup Likely Caused Cancer, Calif. Jury Says
- Justices Offer Practical Approach To Class Appeal Deadline
- Judging A Book: Bashant Reviews 'Doing Justice'
- AbbVie Faces 1st Antitrust Suit Over Humira 'Patent Thicket'
- Sanctions Sought Over Appeal In Synergy Pharma's Ch. 11
- Willkie Nabs Cooley Deals Pro In Silicon Valley
- These Are The Nation's 27 Most Overworked District Courts
- As Judicial Ranks Stagnate, 'Desperation' Hits The Bench
- Fed. Circ. Rejects $750K Award Over Soured Med Device Deal
- Mesh Victims Slam J&J's 'Judge-Shopping' In Pa. Recusal Bid
- Ohio Sues OptumRx To Collect $16M In Alleged Overcharges
- Novartis Eye Care Unit Buys PowerVision for $285M
- 3rd Circ. To Hear Class Cert. Appeal In Lamictal Case
- NC Gene Editing Co. Launches IPO That Could Raise $134M
- If There, Then Here: How Gov't Probes Help Antitrust Plaintiffs
- High Court Won't Take Post-Escobar FCA Materiality Case
- Firms Can Leverage Communications When Economy Is Slow
- Justices Consult SG On Treatment Patent Case Testing Mayo
- Bipartisan Bill Eyes Drug Imports To Boost Competition
- Novartis Aims To Sink 'Inconsistent' Whistleblower Verdict
- OvaScience Investor Seeks Cert. In IVF Treatment Suit
- Purdue Says Cameras Will Turn Opioid Trial Into 'Media Circus'
- Health Hires: Baker McKenzie, Alston & Bird
- Medical Device Co. Hit With Investor Action Over Sale
- Pfizer, Hospira Beat FCA Suit Over Faulty Infusion Pumps
- Fed. Circ. Clarifies Alice In Reviving Supplement Co.'s IP Suit
- Insys Exec Denied Mistrial Bid After 'Salacious' Testimony
- Fetal Tissue Law Fight Belongs In State Court, 7th Circ. Says
- Hikma V. Vanda Exaggerates Treatments' Patent Eligibility
- Fed. Circ. Wants Redo For IP Suit Over Allergan Antipsychotic
- Bayer Must Face Essure Stillbirth Suit, 4th Circ. Rules
- Fed. Circ. Wary Of Ruling On AIA Patent Challenge Meaning
- Merck Antitrust Scheme Didn't Work, UK Says, Ending Probe
- US Trustee Challenges TridentUSA's Ch. 11 Bid For Bonuses
- Delaware Bill Seeks Fee On Opioid Makers Amid Health Crisis
- Monsanto Must Face Couple's Claims At One Trial: Judge
- Stryker Buys Israeli Med Tech Co. In Deal Worth Up To $220M
- Insurers Fight J&J Talc Co.'s Insurance Pay Plan, Claim Rep
- 4 Firms Lead French Biotech Genfit's Estimated $132M IPO
- Penny Stock CEO Can't Slip SEC Suit Over Deceptive Promos
- Investors Fight Keryx Bid To Ditch Kidney Drug Stock Case
- The Future Of The USMCA: 3 Possible Scenarios
- Attys In Opioid Suits Are Holding Big Pharma Accountable
- Ethical Social Media Marketing For Lawyers
- A Chat With Norton Rose Diversity Director Nina Godiwalla
- Litigation Worries Loom As House Mulls Drug-Pricing Bills
- Retrial Jury Hears J&J Mesh Not To Blame For Woman's Pain
- J&J Hit With $29.5M Verdict In Latest Talc Trial
- Claire's Hit With Suit A Day After Asbestos Makeup Recall
- Final Guilty Pleas End Case Of Misbranded Supplements: DOJ
- Bio-Rad Asks 9th Circ. To Rethink Ex-GC's $8M Win
- Pharma Co. Pumped Stock By Hiding Drug Failures, Suit Says
- Insys' $25M Legal Tab For Founder Adds To Its Hazy Future
- Allergan Says It Needs Takeda Docs To Fend Off NJ Suit
- Merck Gets PTAB To Nix Pfizer Vaccine Patent
- Monsanto Bellwether Over Roundup Cancer Risk Goes To Jury
- Deals Rumor Mill: BioNTech, HNA, Malaysia Airlines
- Glancy Prongay Seeks To Lead Nerve-Repair Co. Investor Suit
- Generic-Drug Exclusivity 'Squatting' Draws Bipartisan Heat
- Perrigo Wins $2M In Damages In Flea And Tick Product Row
- Sterigenics Emissions Suit Remanded To State Court
- Pa. Justices Won't Boot Philly Judge From Mesh Trial
- 'Tell The Truth Or Lose Your Soul' Threat Spurs Sanctions Bid
- Synergy Pharma Gets OK For Ch. 11 Plan Releases
- Talc Use Increases Risk Of Ovarian Cancer, Lawmakers Told
- Bernstein Litowitz Seeks $13M In Atty Fees In Medtronic Case
- Paul Weiss, Hogan Steer $660M Deal For Regenerative Med Biz
- 5 Mistakes Law Firms Make When Responding To RFPs
- Fujifilm Pays $890M For Biogen Biologic Manufacturing Site
- Oncologist Testifies Roundup's Link To Cancer Lacks Proof
- J&J Tells Jury It Got 'Out-Lawyered' In Talc Trial
- BakerHostetler, Takeda Unit Dodge Suit Over Voided Patent
- Pfizer To Pay $1M Over Deceptive Drug Coupons In Ore. Deal
- Doctor's Trial Win Doesn't Make DEA's Arrest Wrong: Judge
- Sinovac's Poison Pill Attempt Stalled By Del., Antigua Courts
- Asacol 3rd-Party Payors Want Another Shot At Class Cert.
- Medicare Insider Trading Case Beset By Flaws, 2nd Circ. Told
- Valeant Conflict Wasn't A Crime, Ex-Execs Tell 2nd Circ.
- USPTO Patent Eligibility Rules Still Too Vague, IP Groups Say
- Synthetic Capsule Patent App Fails, Fed. Circ. Says
- Takeaways From FDA's New Bulk Drug Substance Restrictions
- 2nd Circ. Revives Needle-Phobic Walmart Worker's Suit
- Senate Patent Bill To Boost Biosimilars Needs Work, Attys Say
- Feds To Probe Shkreli Using Cellphone To Run Biz From Jail
- Takeda Unit Fights $155M IP Loss, Bayer Wants $27M More
- 4th Circ. Won't Rethink $87M Heparin Suit Coverage Win
- Fed. Circ. Dismisses Moot Appeal Over Opana ER Patents
- Spark's $4.8B Sale To Roche Is 'Unfair,' Investor Claims
- J&J Talc Supplier's Ex-Owners Can't Tap Insurance Funds
- FDA To Quiz Prescribers On Opioid Promotion
- J&J Wants Philly Judge Booted From Further Mesh Trials
- Claire's Makeup Dust-Up Shows Limits Of FDA Oversight
- Health Hires: Quarles & Brady, Reed Smith, Post & Schell
- Taxation With Representation: Skadden, Sullivan, Simpson
- Walgreens Must Face Whistleblower's FCA Suit Over $4 Drugs
- 9th Circ. Gives Costco False Ad Suit Another Shot
- How SEC Could Expand 'Test The Waters' Communications
- Wadler V. Bio-Rad Poses Noteworthy Whistleblower Questions
- J&J Talc Supplier Sues Over Millions In Insurance Funds
- Bill Fighting Pharma Delay Tactics Wins Bipartisan Backing
- Bayer Must Face Suit Over Flintstones 'Complete' Vitamins
- Ex-Insys VP Defiant During Cross-Examination At RICO Trial
- All Biosimilars Will Get Special Names, FDA Says
- Leon Panetta In The Courtroom, Langley And Area 51
- Davis Polk-Led Medical Device Biz Debuts With $97M IPO
- Ex-Pharma Sales Rep Gets 4 Years For $3.5M Rx Scheme
- Chinese Biotech Co. Pulls Back Suit Over Biased H-1B Denials
- Kratom Death Should Spur Gov't Into Action, Pa. Family Says
- Justices Urged To Turn Down PTAB Tribal Immunity Case
- Texas Supplements Co. To Close, Pay $4.7M In Plea Deal
- Gottlieb Leaves Vocal Legacy At FDA
- Hospira Tells Fed. Circ. To Reverse Sedative Patent Loss
- TridentUSA Authorized To Fully Tap $50M Ch. 11 DIP Loan
- Insys CEO Demanded Loyalty Over Integrity, Ex-VP Testifies
- FCA Claim Rightly Axed In $70M Kickback Suit, Judge Says
- Concerns Raised Over Credit Bid In Novum Pharma's Ch. 11
- Copyright Ruling Could Hinder USPTO's High Court Fee Case
- Abbott Ruling Dulls Insurers' 'Knowing Violation' Sword
- Horizon Pharma Facing DOJ Probe Into PBM Payments
- GSK's Avandia Marketing Was Racketeering, 3rd Circ. Told
- Fed. Circ. Won't Revisit Restasis Patent Ruling
- Why I Became A Lawyer: Finding A Voice, And A New Home
- CORRECTED: Novartis Wants Janssen Barred From Disparaging Rival Drug
- Mintz Fraade Says Embattled Biotech's Insurer Owes Bills
- Pa. Justices Will Hear Suit Alleging Cancer-Pesticide Link
- Bristol-Myers Urges Investors To Back $74B Celgene Buy
- Beam Therapeutics Snags $135M In Latest Funding Round
- Aralez Ch. 11 Sale Of Toprol Brand To Deerfield Approved
- DQ Threat In Opioid MDL Could Steer Attys From Public Work
- Endo Wants Perrigo's B12 Nasal Spray Generic Blocked
- Gov't Urged Not To Break Patents To Lower Drug Prices
- 2 Firms Steer Pacira's $220M Medical Device Co. Buy
- Illumina Tells PTAB To Invalidate Columbia Univ. DNA Patent
- Oncology Biotech Co. Secures $145M In Funding
- Insys Founder Used Data To Push Sales Reps, Ex-VP Testifies
- Quest Autodialer Suit Can't Wait On FCC, Judge Told
- FDA Commissioner Scott Gottlieb Resigns
- Weitz & Luxenberg's Quick Win In $25M Fraud Suit Challenged
- Judging A Book: Willett Reviews 'Guilty Pleasures'
- Biogen Beats Ex-Employee's Disability Bias Suit
- PTAB Rejects Challenge To Spinal Surgery Device Patent
- Bard Seeks $67M Damages Award In Vascular Port IP Case
- Calif. Justices Say Pharmacy Customers Can't Force Refunds
- Husch Blackwell Nabs FDA Practice Head From Michael Best
- Monsanto 'Opened Door' To Internal Cancer Report: Judge
- Deals Rumor Mill: Purdue Pharma, Cision, HNA Group
- 2 Firms Guide Biogen's $877M Gene Therapy Co. Buy
- Disney Beats ERISA Suit Over Valeant Shares At 9th Circ.
- Versum Investors Try To Halt Entegris Merger, Favor Merck Bid
- International Pharma Rules Tighten Restrictions On Gifts
- SEC Emphasizes Internal Controls Over Disclosure
- Insys Investors Seek Cert. In Fentanyl Stock Drop Suit
- Women In Law Need Equal Treatment, Not Affirmative Action
- Purdue Hits Mass. AG For 'Scapegoating' Co. In Opioid Suit
- 'Biosimilar V. Biosimilar' Patent Case May Be First Of Many
- Ex-Insys Exec Moves For Mistrial After Salacious Testimony
- New DOJ Opioid Cases Highlight Importance Of Red Flags
- High Court Will Decide USPTO's Win-Or-Lose Atty Fee Rule
- DOJ Atty Warns FCA Targets On Discovery Tactics
- How Firms Can Avoid Conflicts Involving Corporate Affiliates
- Ark.'s Case For Benefits Manager Law Is Flawed, Justices Told
- Novartis Slaps J&J Unit With Psoriasis Drug False Ad Suit
- Ore. Tribe Latest To Join Opioid MDL
- Ex-Doctor Can't Undo 25-Year Prison Sentence At 3rd Circ.
- Pharma Co. Chiasma To Settle Investors' IPO Suit For $18.7M
- DiCello Levitt Expands To NY With Veteran Trial Atty At Helm
- Threat To $74B Celgene Buy About More Than Just Money
- Biotech, Blank-Check IPOs Propel 1 Firm Ahead In February
- Taxation With Representation: Kirkland, Skadden, Gibson
- Convicted NECC Pharmacists Can Make Case For Acquittal
- Specialty Pharma Co. Floats Exec. Bonuses In Ch. 11
- Deals Rumor Mill: Tata Group, Global Switch, Currenta
- Insys Was 'Up Front' With MDs About Bribes, Ex-VP Testifies
- Health Hires: Goodwin, Crowell, Akin Gump, Drinker Biddle
- Versum Rejects $6B Merck Offer, Commits To Entegris Deal
- AI Radiology Co. Investor Seeks Records In Chancery Court
- Visible Diversity Is A Sign Of Organizational Health
- UK Litigation Roundup: Here's What You Missed In London
- Syneos Health Hit With Shareholder Suit Amid SEC Probe
- Simple Secrets For Writing A Killer Brief
- A Defense Attorney's Guide To Successfully Arguing Damages